BioCentury | Jun 23, 2020
Distillery Therapeutics

Repurposing antimalarial drug lumefantrine for glioblastoma

...cancer The antimalarial drug lumefantrine, an FLI1 inhibitor, could treat glioblastoma resistant to radiation and temozolomide...
...and 77.1 μM. Lumefantrine also blocked the cells’ migration and infiltration. In cultured radiation- and temozolomide-resistant...
...50 values of 73.1-185.3 μM. In xenograft mouse models of glioblastoma resistant to radiation or temozolomide...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

...Zai, Novocure secure Optune approval in China NMPA also approved an MAA for Optune plus temozolomide...
BioCentury | Jan 10, 2020
Emerging Company Profile

Empirica: Building a new model for brain cancer

...indication fail over the course of her neurosurgery residency. The standard of care for GBM, temozolomide...
...nature of recurrent GBM, Singh developed a patient-derived xenograft mouse model that is treated with temozolomide...
BioCentury | Oct 3, 2019
Politics & Policy

Experimental GBM vaccine available under U.S. right-to-try program

...the company’s RTT policy, patients must have GBM that has not responded to treatment with temozolomide...
BioCentury | Sep 6, 2019
Clinical News

Opdivo misses in latest GBM readout

...548 trial to treat glioblastoma multiforme, missing one of its primary endpoints. The trial evaluated temozolomide...
BioCentury | May 17, 2019
Clinical News

AbbVie's antibody-drug conjugate misses mark in Phase III GBM trial

...of Clinical Oncology meeting had shown that Depatux-M plus temozolomide improved OS by 32% vs. temozolomide...
...O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated GBM. INTELLANCE-1 evaluated Depatux-M vs. placebo when given with concurrent radiation and temozolomide...
BioCentury | May 9, 2019
Clinical News

May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

...PD-1 inhibitor Opdivo nivolumab plus radiation missed the primary endpoint of improving overall survival vs. temozolomide...
...O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme. The Phase III CheckMate -548 trial is evaluating Opdivo plus temozolomide...
BioCentury | Apr 22, 2019
Distillery Therapeutics

STAG2 identified as target in glioblastoma and Ewing sarcoma

...same lines, STAG2 knockout increased sensitivity to the chemotherapies and dsDNA break repair inhibitors gemcitabine, temozolomide...
BioCentury | Mar 27, 2019
Product Development

GW’s next act

...the combination plus temozolomide had an 83% one-year survival rate vs. 53% for placebo plus temozolomide...
BioCentury | Mar 19, 2019
Distillery Therapeutics

New brain-penetrating RIPK2 inhibitor prodrug for GBM

...identified a naphthoquinone-based compound that inhibited cell viability with greater potency than the generic chemotherapy temozolomide...
Items per page:
1 - 10 of 352